Aster DM Healthcare Intrinsic Value
Aster DM Healthcare (ASTERDM) median intrinsic value is ₹235.69 from 9 valuation models (range ₹157–₹393), vs current price ₹785.65 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read ASTERDM ex-dividend dates for the complete payout history and dividend yield track record.
ASTERDM Valuation Methods Summary — DCF, Graham Number & P/E
Aster DM Healthcare intrinsic value across 9 models vs current price ₹785.65 — upside/downside and value range per method. Analyse ASTERDM shareholder distribution to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹235.69 | ₹188.55 - ₹282.83 | -70.0% | EPS: ₹10.88, Sector P/E: 12x |
| Book Value Method | asset | ₹157.13 | ₹141.42 - ₹172.84 | -80.0% | Book Value/Share: ₹88.34, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹235.69 | ₹212.12 - ₹259.26 | -70.0% | Revenue/Share: ₹94.13, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹314.26 | ₹282.83 - ₹345.69 | -60.0% | EBITDA: ₹1044.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹314.26 | ₹251.41 - ₹377.11 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹235.69 | ₹212.12 - ₹259.26 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹235.69 | ₹212.12 - ₹259.26 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹392.82 | ₹353.54 - ₹432.10 | -50.0% | ROE: 13.5%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹235.69 | ₹212.12 - ₹259.26 | -70.0% | EPS: ₹10.88, BVPS: ₹88.34 |
ASTERDM Intrinsic Value vs Market Price — All Valuation Models
Aster DM Healthcare fair value range ₹157–₹393 vs current market price ₹785.65 across 9 valuation models. For current market price and key ratios, visit ASTERDM screener.
ASTERDM Intrinsic Value Analysis — Undervalued or Overvalued?
Aster DM Healthcare median intrinsic value ₹235.69, current price ₹785.65 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of ASTERDM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aster DM Healthcare (ASTERDM) is ₹235.69 (median value). With the current market price of ₹785.65, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹157.13 to ₹392.82, indicating ₹157.13 - ₹392.82.
Is ASTERDM undervalued or overvalued?
Based on our multi-method analysis, Aster DM Healthcare (ASTERDM) appears to be trading above calculated value by approximately 70.0%.
ASTERDM Financial Health — Key Ratios vs Industry Benchmarks
Aster DM Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.85 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 13.5% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.60x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ASTERDM Cash Flow Quality — Operating & Free Cash Flow
Aster DM Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹425 Cr | ₹425 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹158 Cr | ₹-281 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹1,834 Cr | ₹1,359 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,314 Cr | ₹1,033 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,569 Cr | ₹1,403 Cr | Positive Free Cash Flow | 8/10 |